In vitro synergy of telavancin and rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 61-65

  Pankey, George A ^a   Ashcraft, Deborah S ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Daptomycin; Enterococcus faecium; Etest; Rifampin; Synergy; Telavancin

Indexed keywords

DAPTOMYCIN; LINEZOLID; RIFAMPICIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENTEROCOCCUS FAECIUM; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84875147481     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Plotkin P, Patel K, Uminski A, Marzella N. Telavancin (Vibativ), a new option for the treatment of gram-positive infections. P T. 2011 Mar;36(3):127-138.
2. Vibativ package insert. South San Francisco, CA: Theravance; 2012.
3. Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. Epub 2012 Apr 16.
4. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother. 2004 Mar;53(3):530-532. Epub 2004 Feb 12.
5. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Grampositive cocci. J Chemother. 2006 Feb;18(1):27-32.
6. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother. 2005 Dec;49(12):5166-5168.
7. Lin G, Pankuch GA, Ednie LM, Appelbaum PC. Antistaphylococcal activities of telavancin tested alone and in combination by timekill assay. Antimicrob Agents Chemother. 2010 May;54(5):2201-2205. Epub 2010 Feb 16.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
9. Pillai SK, Moellering RC Jr, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:365-440.
10. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005 Mar;49(3):1127-1134.
11. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S407-S411.
12. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Aug;47(8):2538-2544.